Halozyme Therapeutics (NASDAQ:HALO) Earns Neutral Rating from Analysts at The Goldman Sachs Group

Equities research analysts at The Goldman Sachs Group initiated coverage on shares of Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) in a report issued on Thursday, MarketBeat reports. The firm set a "neutral" rating and a $55.00 price target on the biopharmaceutical company's stock. The Goldman Sachs Group's price target suggests a potential downside of 3.76% from the stock's current price.

HALO has been the topic of a number of other research reports. Benchmark downgraded Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. Leerink Partnrs downgraded Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. Leerink Partners downgraded Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target on the stock. in a research note on Tuesday, May 13th. HC Wainwright reaffirmed a "buy" rating and set a $72.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, May 29th. Finally, Wells Fargo & Company raised their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $62.50.

Halozyme Therapeutics Trading Down 0.8%

NASDAQ:HALO traded down $0.48 during mid-day trading on Thursday, reaching $57.15. 1,242,806 shares of the company's stock traded hands, compared to its average volume of 1,758,707. Halozyme Therapeutics has a 12-month low of $42.01 and a 12-month high of $70.51. The firm has a market capitalization of $7.04 billion, a price-to-earnings ratio of 15.20, a PEG ratio of 0.38 and a beta of 1.15. The company has a debt-to-equity ratio of 3.13, a current ratio of 8.39 and a quick ratio of 7.30. The company has a 50 day moving average price of $55.03 and a 200-day moving average price of $57.01.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The firm had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. During the same quarter in the prior year, the business earned $0.79 EPS. The business's revenue for the quarter was up 35.2% on a year-over-year basis. On average, sell-side analysts predict that Halozyme Therapeutics will post 4.73 earnings per share for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $56.43, for a total value of $1,128,600.00. Following the completion of the sale, the chief executive officer owned 733,719 shares of the company's stock, valued at approximately $41,403,763.17. This trade represents a 2.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey William Henderson sold 4,497 shares of Halozyme Therapeutics stock in a transaction on Monday, April 28th. The stock was sold at an average price of $60.37, for a total value of $271,483.89. Following the completion of the sale, the director directly owned 28,611 shares of the company's stock, valued at approximately $1,727,246.07. The trade was a 13.58% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 64,497 shares of company stock valued at $3,533,884. Corporate insiders own 2.90% of the company's stock.

Institutional Trading of Halozyme Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Wealth Preservation Advisors LLC bought a new stake in shares of Halozyme Therapeutics in the first quarter worth $32,000. SVB Wealth LLC bought a new stake in shares of Halozyme Therapeutics in the first quarter worth $33,000. Bessemer Group Inc. grew its holdings in shares of Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 207 shares during the period. CBIZ Investment Advisory Services LLC bought a new stake in shares of Halozyme Therapeutics in the fourth quarter worth $29,000. Finally, Heck Capital Advisors LLC bought a new stake in shares of Halozyme Therapeutics in the fourth quarter worth $29,000. Institutional investors own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.